Eukaryotic translation initiation factor 4E (eIF4E) expression is associated with breast cancer tumor phenotype and predicts survival after anthracycline chemotherapy treatment

Breast Cancer Research and Treatment

Volumn 141, Issue 1, 2013, Pages 79-88

  Heikkinen, Tuomas ^a   Korpela, Taina ^b   Fagerholm, Rainer ^a   Khan, Sofia ^a   Aittomäki, Kristiina ^d   Heikkilä, Päivi ^d   Blomqvist, Carl ^d   Carpén, Olli ^b,c   Nevanlinna, Heli ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Anthracycline; Breast cancer; Chemotherapy; eIF4E; Metastasis; Triple negative

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; INITIATION FACTOR 4E; KI 67 ANTIGEN; METHOTREXATE; PROGESTERONE RECEPTOR; PROTEIN P53;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; CONTROLLED STUDY; DISTANT METASTASIS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; EPIRUBICIN; EUKARYOTIC INITIATION FACTOR-4E; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PARAFFIN EMBEDDING; PHENOTYPE; PROGNOSIS; PROTEIN BIOSYNTHESIS; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84884289188     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2671-2     Document Type: Article

References (38)

1. Pandolfi PP (2004) Aberrant mRNA translation in cancer pathogenesis: an old concept revisited comes finally of age. Oncogene 23:3134-3137
2. Shaw RJ, Cantley LC (2006) Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441:424-430
3. Gingras AC, Raught B, Sonenberg N (2001) Regulation of translation initiation by FRAP/mTOR. Genes Dev 15:807-826
4. Ruggero D (2009) The role of Myc-induced protein synthesis in cancer. Cancer Res 69:8839-8843
5. Sonenberg N (2008) eIF4E, the mRNA cap-binding protein: from basic discovery to translational research. Biochem Cell Biol 86:178-183
6. Graff JR, Konicek BW, Carter JH et al (2008) Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res 68:631-634
7. De Benedetti A, Graff JR (2004) eIF-4E expression and its role in malignancies and metastases. Oncogene 23:3189-3199
8. Ruggero D, Montanaro L, Ma L et al (2004) The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med 10:484-486
9. Wendel HG, De Stanchina E, Fridman JS et al (2004) Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428:332-337
10. Malina A, Cencic R, Pelletier J (2011) Targeting translation dependence in cancer. Oncotarget 2:76-88
11. Mamane Y, Petroulakis E, Rong L et al (2004) eIF4E-from translation to transformation. Oncogene 23:3172-3179
12. Byrnes K, White S, Chu Q et al (2006) High eIF4E, VEGF, and microvessel density in stage I to III breast cancer. Ann Surg 243:684-690
13. Coleman LJ, Peter MB, Teall TJ et al (2009) Combined analysis of eIF4E and 4E-binding protein expression predicts breast cancer survival and estimates eIF4E activity. Br J Cancer 100:1393-1399
14. Flowers A, Chu QD, Panu L et al (2009) Eukaryotic initiation factor 4E overexpression in triple-negative breast cancer predicts a worse outcome. Surgery 146:220-226
15. Li BD, McDonald JC, Nassar R et al (1998) Clinical outcome in stage I to III breast carcinoma and eIF4E overexpression. Ann Surg 227:756-761
16. Holm N, Byrnes K, Johnson L et al (2008) A prospective trial on initiation factor 4E (eIF4E) overexpression and cancer recurrence in node-negative breast cancer. Ann Surg Oncol 15:3207-3215
17. McClusky DR, Chu Q, Yu H et al (2005) A prospective trial on initiation factor 4E (eIF4E) overexpression and cancer recurrence in node-positive breast cancer. Ann Surg 242:584-590
18. Pettersson F, Yau C, Dobocan MC et al (2011) Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer. Clin Cancer Res 17:2874-2884
19. Tommiska J, Eerola H, Heinonen M et al (2005) Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res 11:5098-5103
20. Syrjakoski K, Vahteristo P, Eerola H et al (2000) Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J Natl Cancer Inst 92:1529-1531
21. Kilpivaara O, Bartkova J, Eerola H et al (2005) Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients. Int J Cancer 113:575-580
22. Eerola H, Blomqvist C, Pukkala E et al (2000) Familial breast cancer in southern Finland: how prevalent are breast cancer families and can we trust the family history reported by patients? Eur J Cancer 36:1143-1148
23. Vahteristo P, Eerola H, Tamminen A et al (2001) A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families. Br J Cancer 84:704-708
24. Eerola H, Heikkila P, Tamminen A et al (2005) Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families. Breast Cancer Res 7:R93-R100
25. Tommiska J, Bartkova J, Heinonen M et al (2008) The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer. Oncogene 27:2501-2506
26. Ahlin C, Aaltonen K, Amini RM et al (2007) Ki67 and cyclin A as prognostic factors in early breast cancer. What are the optimal cut-off values? Histopathology 51:491-498
27. Aaltonen K, Blomqvist C, Amini RM et al (2008) Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers. Clin Cancer Res 14:1976-1983
28. McShane LM, Altman DG, Sauerbrei W et al (2005) Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97:1180-1184
29. Therneau T (2002) A Package for Survival Analysis in S. R package version 2.36-12
30. Peduzzi P, Concato J, Feinstein AR et al (1995) Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol 48:1503-1510
31. Kleiner HE, Krishnan P, Tubbs J et al (2009) Tissue microarray analysis of eIF4E and its downstream effector proteins in human breast cancer. J Exp Clin Cancer Res 28:5
32. Byrnes KW, DeBenedetti A, Holm NT et al (2007) Correlation of TLK1B in elevation and recurrence in doxorubicin-treated breast cancer patients with high eIF4E overexpression. J Am Coll Surg 204:925-933
33. Beslija S, Bonneterre J, Burstein HJ et al (2009) Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 20:1771-1785
34. Hsieh AC, Ruggero D (2010) Targeting eukaryotic translation initiation factor 4E (eIF4E) in cancer. Clin Cancer Res 16:4914-4920
35. Wendel HG, Silva RL, Malina A et al (2007) Dissecting eIF4E action in tumorigenesis. Genes Dev 21:3232-3237
36. Ding Q, He X, Xia W et al (2007) Myeloid cell leukemia-1 inversely correlates with glycogen synthase kinase-3beta activity and associates with poor prognosis in human breast cancer. Cancer Res 67:4564-4571
37. Li Y, DeFatta R, Anthony C et al (2001) A translationally regulated Tousled kinase phosphorylates histone H3 and confers radioresistance when overexpressed. Oncogene 20:726-738
38. Sunavala-Dossabhoy G, Fowler M, De Benedetti A (2004) Translation of the radioresistance kinase TLK1B is induced by gamma-irradiation through activation of mTOR and phosphorylation of 4E-BP1. BMC Mol Biol 5:1